Henry Pharma SPRL
Henry Pharma reported total assets of €3.63m at the end of the 2025 financial year (annual accounts filed with the NBB on 01 Jun 2026).
The score of Henry Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +22 % Total assets +1 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Henry Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 01 Jun 2026
- Year ended 31 Dec 2024filed on 07 Aug 2025
- Year ended 31 Dec 2023filed on 03 Jul 2024
- Year ended 31 Dec 2022filed on 29 Jun 2023
- Year ended 31 Dec 2021filed on 16 Jun 2022
Henry Pharma's financial analysis
- Solvency31.1%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Henry Pharma
Henry Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0688.865.294
- VAT number
- BE0688865294
- Peppol
- Registered · 0208:0688865294 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 25 Jan 2018
- Registered office
- 6238 Pont-à-Celles
- Latest accounts
- 2025 · filed on 01 Jun 2026
- Activity
- Activities of holding companies (NACE 64210)
Henry Pharma (SPRL) has been based in Pont-à-Celles since 2018, active in: activities of holding companies. For 2025, it reports a net profit of 60,103 € and equity of €1.13m; its revenue is not published. Its solvency stands at 31.1%, below the median of its sector (46.9%).
Companies similar to Henry Pharma
Companies in the same business, of comparable size and area, outside its group.
- Partfin Activities of holding companies Saint-Nicolas · balance sheet €3.63m
- Gidaco Activities of holding companies Diepenbeek · balance sheet €3.64m
- Tivan Invest Activities of holding companies Alveringem · balance sheet €3.64m
- Gisti Management Activities of holding companies Woluwe-Saint-Pierre · balance sheet €3.64m
- Jagico Activities of holding companies Beringen · balance sheet €3.64m
- Hanin Pharma Activities of holding companies Jette · balance sheet €3.62m
- Decath Holding Activities of holding companies Wortegem-Petegem · balance sheet €3.62m
- Vandapower Group Activities of holding companies Ghent · balance sheet €3.62m
Frequently asked questions about Henry Pharma
What is the revenue of Henry Pharma?
Henry Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Henry Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0688865294 for Henry Pharma, if the company is VAT-registered. Its company number (CBE) is 0688.865.294.
Where is the registered office of Henry Pharma?
According to the CBE register, the registered office of Henry Pharma is in 6238 Pont-à-Celles.
What is the equity of Henry Pharma?
At the close of the 2025 financial year, the equity of Henry Pharma amounts to 1,129,543 €, a solvency of 31.1% of total assets.
Who manages Henry Pharma?
The register lists 1 active mandates at Henry Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Henry Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →